Perioperative Intravenous Nimodipine Trial
Sponsor: University of Ioannina • ClinicalTrials.gov ID: NCT07048522
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The role of perioperative IV administration of nimodipine, an L-type calcium channel antagonist which is capable of crossing the blood-brain barrier, on peri-operative opioid and anesthetics requirements, pain intensity, opioid-related side effects and early postoperative bowel mobility in patients undergoing surgical treatment for bowel cancer with open radical colectomy remains scarcely explored. A prospective double-blind, randomized controlled trial investigating the effect of perioperative IV administration of nimodipine in patients undergoing open colectomy for cancer treatment is therefore conducted.
Interventions
-
Nimodipine
(Drug)
A continuous dose of 2 mg/h (10 ml/h) of nimodipine solution will be administered continuously one (1) h prior to start of operation until 24 h after the end of the procedure.
-
Isotonic Saline
(Drug)
A continuous dose of 10 ml/h of normal saline solution will be administered continuously one (1) h prior to start of operation until 24 h after the end of the procedure.
Eligibility criteria
Conditions
Locations
- St. Andrews General Hospital of Patras, GREECE — Pátrai, Achaea, Greece
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record